Overview
Femara is classified as a PCT (post-cycle therapy) and ancillary compound. Non-steroidal, reversible aromatase inhibitor.
With a half-life of ~1.8 days (42 hours), Femara supports less frequent dosing schedules. Taken orally, it has a bioavailability of approximately 99% via its primary route.
Half-life approximately 42 hours. Near-complete oral bioavailability (~99%). Highest potency among commonly used aromatase inhibitors. One-compartment model.
Mechanism of Action
Femara's pharmacological activity involves the following key pathways:
Aromatase Inhibition
Femara reduces the conversion of androgens to estrogens by inhibiting the aromatase enzyme. This directly lowers circulating estrogen levels.
Competitive Binding
Femara is a non-steroidal, reversible aromatase inhibitor. It competes with the natural substrate for the enzyme's active site.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
0.25 mg/day
Route
Oral
Frequency
Every other day
Duration
4-8 weeks
Dose
2.5 mg/day
Route
Oral
Frequency
Every other day
Duration
4-8 weeks
Frequently Asked Questions
What is letrozole and how does it work?
Letrozole (brand name Femara) is a third-generation non-steroidal aromatase inhibitor and the most potent AI available. It reversibly binds to the cytochrome P450 component of the aromatase enzyme, blocking the conversion of androgens to estrogen. At standard doses, letrozole is capable of suppressing circulating estradiol by up to 98%, making it significantly more potent than both anastrozole and exemestane.
What is the half-life of letrozole and how long until steady state?
Letrozole has a terminal elimination half-life of approximately 2 days (48 hours). Steady-state plasma concentrations are reached after approximately 10 days of consistent daily dosing, at which point levels are roughly 7 times higher than after a single dose. This accumulation effect means that the drug’s impact on estradiol builds progressively over the first 1–2 weeks.
Why is letrozole considered the most potent aromatase inhibitor?
Clinical studies have demonstrated that letrozole produces near-complete inhibition of aromatase in peripheral tissues, with greater suppression of estrogen than is achieved with anastrozole or exemestane. Daily doses as low as 0.5 mg can suppress estradiol by 75–95%. This potency is why community protocols frequently use doses well below the standard 2.5 mg tablet – often 0.25–0.5 mg – to avoid excessive estrogen suppression.
Can letrozole be used for gynecomastia?
Letrozole’s extreme potency has led to its off-label use in attempts to address estrogen-driven gynecomastia. The rationale is that aggressive estradiol suppression may reduce glandular tissue proliferation. Results are most commonly observed when tissue development is recent (weeks to months). Long-standing tissue that has become fibrotic is unlikely to respond to estrogen suppression alone. Doses commonly reported in this context range from 0.5–2.5 mg every other day, though such aggressive suppression carries significant side effect burden.
What are the risks of letrozole overdosing?
Due to its extreme potency, letrozole overdosing is one of the most commonly reported issues. Symptoms of crashed estrogen include severe joint pain, complete loss of libido, pronounced fatigue, brain fog, dry and cracking skin, mood disturbances, and impaired bone mineral density. Because letrozole is a reversible inhibitor with a 2-day half-life, recovery typically begins within 3–5 days of discontinuation, but the experience is uniformly described as highly unpleasant.
What is the typical letrozole dosage for estrogen management?
Due to its potency, letrozole is typically used at much lower doses than the standard 2.5 mg tablet. Community protocols commonly report 0.25–0.5 mg every other day for general estrogen management alongside testosterone. The 2.5 mg dose is generally reserved for aggressive interventions and carries significant risk of estrogen suppression. Tablet splitting or liquid formulations are frequently used to achieve the lower doses. Bloodwork-guided titration is considered essential given the narrow margin between effective management and overcorrection.